Doxoves® is produced using a similar high-quality manufacturing process that ensures consistent batch-to-batch characteristics, a tight particle size distribution, and high drug encapsulation efficiency. Researchers have the option to choose between two drug concentrations, with a standard 2mg/mL similar to Doxil® and a higher concentration of 4.0mg/mL (40mM lipid) for higher-dose experiments. The characteristics, stability, and pharmacokinetics of Doxoves® are comparable to those of the commercial product Doxil®. Cryo-TEM studies have confirmed that the encapsulated doxorubicin in Doxoves® forms the same rod-like structures as in Doxil®. The pharmacokinetic profiles of two batches of Doxoves® were excellent, with half-lives of 30-40 hours similar to those of Doxil®.
